Skip to main content
Top
Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie 8/2019

01-08-2019 | Heparin | Correspondence

Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient

Authors: Ian Downie, MD, Zachary Liederman, MD, FRCPC, Kartiga Thiyagarajah, MD, Rita Selby, MBBS, FRCPC, MSc, Yulia Lin, MD, FRCPC, CTBS

Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Issue 8/2019

Login to get access

Excerpt

To the Editor,
Table
APTT and anti-Xa assay values as well as factor VIII, fibrinogen, and antithrombin levels of the patient described
Postoperative day
Time
APTT*
(23–30 sec)
Anti-Xa assay†
(0.3–0.7 IU·mL−1)
FVIII ‡
(> 0.50 IU·mL−1)
Fibrinogen
(> 1.70 g·L−1)
Antithrombin
(> 0.33 IU·mL−1)
28
13:18
17.1
0.09
6.286
-
-
 
15:57
34.4
0.73
6.517
-
-
 
17:08
50.6
0.94
5.471
-
-
29
17:56
-
-
6.514
2.29
1.14
30
01:53
17.1
-
5.575
-
-
 
20:53
-
-
-
2.11
-
33
07:22
64.0
1.22
6.199
-
-
34
18:18
44.3
0.71
6.572
-
-
The target APTT range during this time period was 70–90.9 sec. APTT = activated partial thromboplastin time; IU = international units
*APTT reagent – Dade Actin® FS on Sysmex CS 5100; †Anti-Xa assay – Innovance ® Heparin on Sysmex CS 5100; ‡One stage Factor VIII assay on Sysmex CS 5100
Literature
1.
go back to reference Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.CrossRef Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.CrossRef
2.
go back to reference Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 282-98. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 282-98.
3.
go back to reference Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2: 581-4.CrossRefPubMed Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2: 581-4.CrossRefPubMed
4.
go back to reference Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.CrossRefPubMed Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.CrossRefPubMed
5.
go back to reference Young E, Prins M, Levine M, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.CrossRefPubMed Young E, Prins M, Levine M, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.CrossRefPubMed
Metadata
Title
Pseudo heparin resistance caused by elevated factor VIII in a critically ill patient
Authors
Ian Downie, MD
Zachary Liederman, MD, FRCPC
Kartiga Thiyagarajah, MD
Rita Selby, MBBS, FRCPC, MSc
Yulia Lin, MD, FRCPC, CTBS
Publication date
01-08-2019
Publisher
Springer International Publishing
Keyword
Heparin
Published in
Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Issue 8/2019
Print ISSN: 0832-610X
Electronic ISSN: 1496-8975
DOI
https://doi.org/10.1007/s12630-019-01391-y

Other articles of this Issue 8/2019

Canadian Journal of Anesthesia/Journal canadien d'anesthésie 8/2019 Go to the issue